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Introduction
Genetic polymorphisms are defined as variations in DNA
that are observed in 1% or more of the population.
Genetic polymorphisms may alter protein structure and
function through a single nucleotide base substitution in a
gene’s coding region, and may increase or decrease gene
expression either by affecting mRNA stability when occur-
ring in a gene’s 3′ untranslated region or by altering tran-
scription factor binding when occurring in the 5′ promoter
region. Alternatively, a polymorphism may have no discern-
able effect on the protein product and may lie within DNA
regions that are not involved in gene transcription or trans-
lation. Polymorphisms that exist in these regions as varia-
tions in repeat sequences throughout the genome have
served the basis for genetic linkage analysis [1].
The study of genetic polymorphisms promises to help
define pathophysiologic mechanisms, to identify individu-
als at risk for disease and to suggest novel targets for
drug treatment. The methodology to study polymorphisms
is simple, requiring only access to a polymerase chain
reaction machine, funding for reagents, and DNA samples
from cases and controls (Fig. 1 illustrates the methods
used to detect polymorphisms). The seemingly unlimited
potential of genetics to help predict who will get lung
disease or who, once diagnosed with disease, will have an
unfavorable prognosis has inspired many investigators to
jump on the bandwagon of studying genetic polymor-
phisms. While progress in understanding and treating pul-
monary diseases has occurred through investigating
genetic polymorphisms, the limitations and potential pit-
falls of this approach may be under-appreciated.
Approaches to genetic polymorphism
analysis
Polymorphisms are most often assessed as contributing
to disease susceptibility or progression using association
studies [2]. We will thus focus on factors affecting the
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quality of association study design. To identify susceptibil-
ity loci, association studies involve typing a genetic poly-
morphism in unrelated affected individuals and in a group
of healthy, ethnically matched controls. A given polymor-
phism is associated with the disease if that allele occurs at
a significantly higher frequency among cases compared
with controls. When evaluating polymorphisms as disease
progression factors, rather than comparing affected
individuals with healthy controls, investigators compare
individuals with extreme phenotypes. If a significant asso-
ciation emerges, three possibilities exist: the polymor-
phism itself is the locus of interest, the polymorphism is in
linkage disequilibrium (LD) with the locus, or confounding
factors are present.
LD exists when alleles at two separate genetic loci are
found more often together in a population than would be
expected based on their individual allelic frequencies. Pos-
sible causes of LD include recent mutation, founder
effects, or selection. Another potential cause of LD is a
population admixture, where two populations that have
been apart for a significant amount of time (and subse-
quently may have very different allelic frequencies at
numerous genetic loci) combine to form a hybrid popula-
tion. Depending on the nature of the admixture, the result-
ing LD can be expanded beyond distances generally
observed in more stable populations [3]. The best esti-
mates of LD within an outbred population suggest that LD
is unlikely to extend over distances more than 1–2 cM or
about 1–2 million base pairs, although in an inbred popu-
lation, such as the Hutterities, LD may exist over 10 times
that distance [4].
Confounding factors must be considered particularly when
polymorphisms identified in one study cannot be duplicated
in a similar ethnic group. One confounding factor is popula-
tion stratification. This may occur with an unbalanced ethnic
admixture, such as a Caucasian admixture in the African-
American gene pool [5]. Fortunately, this problem can be
overcome by careful planning in either the analysis or study
design phase [6]. Family-based association studies, which
require the genotyping of affected individuals and their
parents (and/or unaffected sibs), are specifically designed
to control for the genetic background that can cause con-
Figure 1
(a) Several methods to detect specific nucleotide changes (polymorphisms) exist. One method relies on hybridization of oligonucleotides of known
sequences to target DNA. The target DNA is generally obtained using the polymerase chain reaction and specific primers. Allele-specific
oligonucleotides are then used to detect single base changes in the DNA samples. Typically, target DNA is immobilized on a solid support and
denatured. Labeled (radioactive or fluorescent) oligonucleotides are then allowed to anneal. Complementary sequences bind while noncomplementary
sequences do not. Sequences that match the oligonucleotide are detected by fluorescence or when the oligonucleotide is radiolabeled by exposure to
X-ray film. (b) Another means of rapid screening for DNA variations relies on detecting conformational changes in secondary structure caused by the
nucleotide sequence alteration. The change in structure can be detected in a number of ways including denaturing gradient electrophoresis and
denaturing gradient high-performance liquid chromatography. SSCP, single-stranded conformational polymorphism. (c) Base mismatch methods begin
with creating heteroduplexes between wild-type or normal DNA and target DNA. Heteroduplexes with mismatches are detected by enzymatic or
chemical cleavage, with the cleavage products resolved by electrophoresis. (d) DNA sequencing can also be used to detect polymorphisms but is the
most labor intensive. The method involves synthesis of DNA using DNA polymerase. Dideoxynucleotides are included in the synthesis mix to randomly
terminate synthesis at each nucleotide in the sequence. Generally, each dideoxy nucleotide is labeled with a flourescent tag. Terminated strands are
separated by denaturing gel or capillary electrophoresis and are detected using fluorescence.Page 3 of 8
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founding. Two common test statistics for these types of
studies are the transmission disequilibrium test (TDT) and
the haplotype relative risk (HRR). The TDT compares the
frequency with which each allele is transmitted from a het-
erozygous parent to an affected offspring [7,8]. The HRR is
similar to the TDT, but compares transmission of genotypes
(haplotype) rather than alleles [9,10].
A critical factor to consider in genetic polymorphism
studies is the choice of what phenotype to investigate. In
fact, many studies that have evaluated genetic polymor-
phisms have been hindered by the case sample containing
multiple phenotypes. For example, some studies of asthma
have included samples consisting of patients with intrinsic,
extrinsic, adult onset, mild and severe asthma. Studies that
seek to determine whether an association between a poly-
morphism and disease exists can be greatly improved by
studying a more narrowly defined intermediate phenotype.
In the case of asthma, intermediate phenotypes include
total IgE and bronchial hyperresponsiveness. Another con-
sideration is that genes responsible for disease suscepti-
bility may not be the same genes involved with disease
progression. It may be beneficial to limit the sample to those
with a particular stage or severity of disease. For example, to
evaluate chronic obstructive pulmonary disease (COPD)
candidate genes, investigators have focused on patients
with severe early onset COPD [11,12].
Association studies are limited to evaluating DNA polymor-
phisms near or within candidate genes. To perform a
genome screen to search for candidate genes, linkage
analysis using families or affected siblings is required.
Linkage analysis is comprehensive and locates genes that
exert a major effect on disease susceptibility, but linkage
analysis has relatively low power and will fail to detect
genes conferring only mild to moderate disease risk. For
instance, if a disease susceptibility allele exerts a twofold
disease risk compared with the wild-type allele, several
hundred to several thousand families need to be typed, a
sample size that may not be achievable. Association studies
have greater power, but associations are detected over
much smaller genetic regions (thousands of base pairs)
compared with that detected by linkage analysis (millions of
base pairs). To perform a genome scan with association
studies, tens of thousands of markers would be needed,
which is not possible with current technology; although it is
anticipated that this may soon be possible [13].
Most lung diseases require some type of environmental
inciting agent to be manifest. For most complex diseases
where genetic susceptibility alone accounts for only a
fraction of disease variation, not considering the environ-
ment can severely underpower gene-finding studies. Fur-
thermore, genome screens or association studies
performed on populations not stratified nor selected on
the basis of environmental exposure may only identify
genes for which the relevant environmental exposure is
ubiquitous in that population. For example, studying a
random population of asthmatics selected from the
Midwest region of the US would stand a reasonable
chance of identifying genes important in determining
house dust mite response, but would not be likely to iden-
tify genes important in isocyanate-induced asthma.
Gene–environment interaction may manifest in various
ways, including differential exposure risk effects based on
an individual’s genotype, or differential gene risk effects
based on an individual’s exposure. Methods to study
gene–environment interaction have been reviewed by
Yang and Khoury [14]. Two main interactions exist: statis-
tical and biologic. A statistical interaction of risk factors
(gene and environment) involves the coefficient of the
product term of the genetic and environmental risk factors
with the interaction measured in terms of departure from a
multiplicative model. This method is arbitrary, model
dependent and can ignore interaction or synergy on the
biologic level. In the biologic interaction model, interaction
between two factors is defined as their co-participation in
the same causal mechanism to disease development, and
in some instances may only be detectable in terms of a
departure from an additive model.
Disease gene associations
Having reviewed the general approach for evaluating poly-
morphisms, we turn to some recent examples. Table 1
displays examples of recently published reports of poly-
morphisms that were evaluated in a variety of lung diseases.
Chronic beryllium disease
Genetic polymorphisms in human leukocyte antigen (HLA)
genes associated with resistance or susceptibly to
disease exist. HLA polymorphisms determine immune
response variation to individual antigens, including
autoantigens, and thus make for excellent candidate
genes for a variety of immune-mediated disorders [15].
One striking example is in the genetic analysis of patients
with chronic beryllium disease. These studies revealed an
association with alleles of HLA-DPB1 encoding a DP beta
chain with glutamic acid at residue 69 [16]. Individuals
with glutamic acid at position 69 have nearly a 10-fold
increased disease risk [17]. Furthermore, functional
studies have demonstrated that the presence of glutamic
acid at residue 69 is essential for reactivity in T-cell clones
generated from three patients with disease [18]. Few
examples in pulmonary diseases exist where the HLA
association with disease risk is as strong.
Given the clinical and pathohistologic similarities of
chronic beryllium disease and sarcoidosis, we have evalu-
ated this same polymorphism in sarcoidosis patients and
controls, and found no association [19]. The lack of asso-
ciation of glutamic acid at residue 69 in sarcoidosis illus-
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Table 1
Examples of recently published studies of polymorphisms in lung disease
Disease Reference Summary
ARDS
Polymorphisms of human SP-A, SP-B and SP-D genes:  [40] Data presented suggest that SP-B or a linked gene contributes 
association of SPB Thr131ILE with ARDS to susceptibility to ARDS
Asthma
Effect of polymorphism of the β-2-adrenergic receptor on  [41] Arg/Arg subjects who used albuterol regularly had AM PEF 
response to regular use of albuterol in asthma lower than Arg/Arg patients who had used albuterol as needed 
only. Subjects homozygous for glycine at β-2-adrenergic 
receptor-16 showed no such decline
Association of a promoter polymorphism of the CD14 gene  [42] –159 C to T promoter polymorphism in the CD14 gene was 
and atopy found associated with expression of a more severe allergic 
phenotype
The role of the C–C chemokines receptor-5 Delta32  [43] Data indicate that the CCR5*D32 allele is not a genetic risk 
polymorphism in asthma and in the production of regulated  factor for the development of asthma and does not influence 
on activation, normal T cells expressed and secreted disease severity nor influence RANTES production
COPD
TNF-α gene promoter polymorphism in COPD [44] TNF gene promoter allele was not found to influence the risk of 
developing COPD in a Caucasian population of smokers and 
there was no association with severity of airflow obstruction
A polymorphism in the TNF-α gene promoter region may  [45] Homozygosity for adenine substitution polymorphism at 
predispose to a poor prognosis in COPD position –308 was found associated with more severe airflow 
obstruction and a worse prognosis
Microsatellite polymorphism in the heme oxygenase-1  [46] Findings suggest that the large size of a GT(n) repeat in the 
gene promoter is associated with susceptibility to emphysema heme oxygenase-1 gene promoter may reduce the gene’s 
inducibility by reactive oxygen species in cigarette smoke, thus 
resulting in emphysema
Cystic fibrosis
HLA class II polymorphism in cystic fibrosis. A possible  [47] DR7 allele was significantly associated with an increase in total 
modifier of pulmonary phenotype IgE and Pseudomonas aeruginosa colonization in cystic fibrosis 
patients
An α1-antitrypsin enhancer polymorphism is a genetic  [48] An enhancer polymorphism in the AAT gene was found 
modifier of pulmonary outcome in cystic fibrosis associated with better pulmonary prognosis in cystic fibrosis 
patients
Hypersensitivity pneumonitis
Major histocompatibility complex and TNF-α polymorphisms  [49] Results suggest that genetic factors located with the major 
in pigeon breeder’s disease histocompatibility complex region contribute to the 
development of pigeon breeder’s disease
TNF-α –308 promoter gene polymorphism and increased  [50] The frequency for the TNFA2 allele, a genotype associated with 
TNF serum bioactivity in farmer’s lung patients high TNF-α production in vitro, was significantly higher in 
farmer’s lung patients
Idiopathic pulmonary fibrosis
Analysis of TNF-α, lymphotoxin alpha, TNF receptor II, and  [28] This is the first paper to suggest that disease progression in 
IL-6 polymorphisms in patients with idiopathic pulmonary  idiopathic pulmonary fibrosis may be linked to a particular 
fibrosis genetic marker or to functional polymorphisms
Sarcoidosis
HLA-Gm/κ interaction in sarcoidosis. Suggestions for a  [51] This study addresses the interplay between IgG heavy chain/κ
complex genetic structure light chain markers and major histocompatibility complex genes
Lack of association with IL-1 receptor antagonist and IL-1β [52] No bias in the IL-1 receptor antagonist and IL-1β genotype was 
gene polymorphisms in sarcoidosis patients found in Japanese sarcoidosis patients
CC chemokine receptor gene polymorphisms in  [53]  CCR5Delta32 and CCR2-64I were found associated with 
Czech patients with pulmonary sarcoidosis sarcoidosis
Silicosis
Polymorphisms of the IL-1 gene complex in coal miners  [54] This is the first report showing an association between the IL-1 
with silicosis receptor antagonist polymorphism and silicosis
PEF, Peak expiratory flow; ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; HLA, human leukocyte
antigen; IL, interleukin; TNF, tumor necrosis factor.trates the pitfall of studying polymorphisms in candidate
genes, however attractive, chosen based on a limited
understanding of the pathophysiology of disease.
Chronic obstructive pulmonary disease
That only 10–20% of cigarette smokers develop sympto-
matic COPD suggests that genetic factors are likely to be
important. In addition, several studies have shown an
increased prevalence of COPD within families. COPD
thus appears to be ripe to investigate genetic polymor-
phisms in disease susceptibility [20].
Studies have implicated oxidant–anti-oxidant interaction in
the pathogenesis of COPD, which led Smith and Harrison to
investigate genetic polymorphisms of the xenobiotic metabo-
lizing enzyme, microsomal epoxide hydrolase (mEH) [21]. A
mEH slow allele and a mEH fast allele exist. The homozy-
gous state for the slow alleles results in very slow microso-
mal epoxide hydrolase activity. The presence of epoxides in
the lung for longer periods following cigarette smoke expo-
sure could lead to greater tissue damage and inflammation.
The study design and statistical analysis in the Smith and
Harrison study is commonly encountered in reports of
disease-associated genetic polymorphisms. The investiga-
tors studied blood donor controls (n = 203), patients with
asthma (n = 57), patients with lung cancer (n = 50),
patients with COPD (n = 68) and patients with emphy-
sema (n = 94). The proportion of individuals with innate
slow activity was significantly higher in both the COPD
group and the emphysema group than in the control
group: COPD 19% versus control 6%, and emphysema
22% versus control 6%. The odds ratios for homozygous
slow activity versus all other phenotypes were 4.1 for
COPD and 5.0 for emphysema. Koyama and Geddes
have noted that caution is needed over the interpretation
of these findings [22]. The groups are small and the
emphysema group was unusual, being defined from the
morbid anatomy of lung samples resected for cancer.
Sakao et al. have argued that tumor necrosis factor (TNF)-α,
a potent pro-inflammatory cytokine, may be involved in the
development of COPD [23]. TNF-α has been reported to
be elevated in bronchoalveolar lavage, bronchial biopsies
and induced sputum of COPD patients. A polymorphism at
position –308 of the TNF-α gene promoter is associated
with alteration of TNF-α secretion in vitro [24]. The polymor-
phism consists of a guanine to adenine substitution. The
guanine allele was denoted as 1 and the adenine allele as 2.
TNF-α-308*2, the rarer allele, has been associated with
higher baseline and induced expression of TNF-α.
Sakao et al. compared TNF-α-308 1/2 allele frequencies
in 106 Japanese patients with 110 asymptomatic smoker/
ex-smoker control subjects matched for sex and age, and
129 population control blood donors. The authors
reported that TNF-α-308 1/2 alleles were significantly
associated with the presence of smoking-related COPD.
Allele frequencies were significantly different among the
groups: in patients with COPD, the 1/2 allele frequencies
were 0.835/0.165; in smoker/ex-smoker control subjects,
0.918/0.082; and in the population control subjects,
0.922/0.078. However, the TNF-α-308*2 allele was not
found to be associated with COPD in a white population.
Furthermore, studies have been inconsistent in demon-
strating an association with the presence of the TNF-α-
308*2 allele in a number of inflammatory diseases such as
sarcoidosis and asthma [25–27].
Sandford et al. noted that widely divergent rates of decline
in lung function in smokers would be a robust phenotype
for detecting genes that contribute to COPD severity [11].
This association study has enhanced features, including
reducing phenotypic heterogeneity by focusing on the
decline of lung function rather than COPD and by compar-
ing extreme phenotypes. From 5887 male and female
smokers recruited to the Lung Health Study (LHS) con-
ducted by the National Heart, Lung and Blood Institute,
Sandford et al. selected 283 smokers with the fastest rate
of decline of forced expiratory volume in 1 s, and 308
smokers who had no decline. All subjects were white and
continued to smoke during the 5-year period of the LHS.
These subjects were genotyped for polymorphisms in α1-
antitrypsin, mEH, vitamin D binding protein, and TNF-α and
TNF-β genes. TNF-β is also known as lymphotoxin alpha.
The authors found [11] that the α1-antitrypsin MZ geno-
type and the mEH His113/His139 slow haplotype were
associated with increased rate of decline of lung function.
Both of these associations were strong when the subject
had a family history of COPD, suggesting an interaction
with other familial risk factors. No association of the TNF
haplotypes with rate of decline of lung function was found.
It would be helpful to re-evaluate these polymorphisms in a
family-based association study using TDT or HRR. Unlike
asthma or sarcoidosis, however, COPD generally occurs
later in life. Those recruited to the LHS range in age from 35
to 60 years, making it more difficult to recruit their parents.
Idiopathic pulmonary fibrosis
A strong link between overexpression of pro-inflammatory
mediators and idiopathic pulmonary fibrosis (IPF) exist.
Recently, Pantelidis et al. reported an evaluation of TNF,
lymphotoxin alpha, TNF receptor II and IL-6 polymor-
phisms in patients with IPF [28]. These investigators,
through their thorough analysis, raised several issues
regarding genetic polymorphism studies. While allele fre-
quencies did not differ between a normal, white, British
control population and a sample with IPF, they did observe
a significant increase in the frequency of a particular TNF
haplotype in females with IPF compared with males.
Similar gender association has been observed in the distri-
Available online http://respiratory-research.com/content/3/1/15
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raises the issue that polymorphisms may act differently in
women, and separate analysis of associations with poly-
morphisms in women may need to be considered. Pante-
lidis  et al. [28] also noted an increased frequency of
co-carriage of the IL-6 (intron 4G) allele located on chro-
mosome 7p21-p14 and the TNF receptor II (1690C) allele
located on chromosome 1p36.2. Since complex dis-
orders, such as IPF, can be expected to involve several
genes, combination of alleles on different chromosomes
may need to be considered.
Tuberculosis
Convincing evidence exists that genetic factors are impor-
tant in tuberculosis susceptibility. Stead et al. found,
among over 25,000 tuberculin-negative nursing home res-
idents, that black subjects were twice as likely to become
infected with tuberculosis as white subjects living in the
same environment [30]. Twin studies in tuberculosis have
consistently found much higher disease concordance
among monozygotic than dizygotic twins [31].
Studies on murine models of susceptibility to mycobacter-
ial infection led to the discovery of the natural resistance-
associated macrophage protein gene and its human
homolog NRAMP1 [32,33]. Bellamy et al. found a signifi-
cant association of NRAMP polymorphisms and tuberculo-
sis in a Gambian population (n = 800) [34]. Functional
studies indicate that NRAMP1 is involved in the early
stages of macrophage priming and activation, making
NRAMP1 an attractive candidate gene for both tuberculo-
sis and sarcoidosis [35].
We analyzed the same NRAMP gene polymorphisms found
associated with tuberculosis in an association case–control
study of 157 African-American sarcoidosis patients and
111 control subjects [36]. These polymorphisms included a
microsatellite repeat in the 5′ region (5′-CA), a non-conserv-
ative single base substitution at codon 543 changing aspar-
tic acid to asparagine (D543N) position 543, a TGTG
deletion in the 3′ untranslated region and a single
nucleotide change in intron 4. Our results, in contrast to
those reported in tuberculosis patients, showed that the
genotypes found associated with tuberculosis were under-
represented in the sarcoidosis patients, suggesting a poten-
tial protective effect in sarcoidosis. One could speculate a
mechanism whereby altered NRAMP expression could lead
to susceptibility to tuberculosis and a protective effect in
sarcoidosis, but it is more important to confirm these find-
ings. We are therefore presently analyzing NRAMP polymor-
phisms in 240 sarcoidosis families using TDT.
Pharmacogenetics
An exciting development has been the evaluation of
genetic polymorphisms in determining treatment
response. The best data concerns beta-2-adenoreceptor
polymorphisms. It appears that individuals who are
homozygous for the glycine 16 variant of the adenorecep-
tor, which downregulates to a greater extent than other
forms of the receptor, show a reduced response following
chronic beta-agonist use [37,38]. Treatment response to
5-lipoxygenase inhibitors also appears determined by
polymorphisms in the promoter regions of this gene [39].
Bandwagon or breakthrough?
Several reasons exist why the genetic evaluation of lung
diseases is not proceeding as rapidly as one might expect.
There is a need to apply several criteria (Table 2) in
designing high-quality association studies and in the inter-
pretation of their results.
Accurate narrow definition of the phenotype
Disease heterogeneity may obscure association between
a disease subtype and a polymorphism. By narrowing the
phenotype, the investigator improves chances of uncover-
ing an association. An alternative strategy is to analyze an
intermediate biologic or clinical phenotype (e.g. elevated
IgE in patients with asthma).
Large sample size
Given the number of conflicting reports of disease-associ-
ated genetic polymorphisms, it is important to point out
that most negative studies lack power. A strong inverse
relationship between the allele frequency in a population
and the sample size required to test the allele contribution
to the phenotype exists. Furthermore, complex diseases
are polygenic in nature and we generally evaluate one
genetic variant or a small fraction of genetic variants of the
many genes likely to contribute, thus further requiring a
larger sample size. Networks of investigators are probably
needed when addressing complex diseases. Given the
cost and time required to recruit such populations, investi-
gators should be encouraged to enter into large-scale col-
laborations. For example, in the US, in the multicenter A
Case Control Etiologic Sarcoidosis Study (ACCESS), 10
clinical centers recruited over 700 cases and 700 con-
trols; and in the Sarcoidosis Genetic Analysis (SAGA)
study, 11 centers are recruiting 350 affected sibling pairs
and their family members for linkage analysis.
Well-matched controls
Besides lack of power, most genetic polymorphism
studies are confounded by lack of well-matched controls.
In fact, rather than the recruitment of patients, the real
challenge often lies in the recruitment of controls. Control
groups are generally confounded by a selection bias that
may influence the genetic makeup of that population.
Biological plausibility and functional significance of
candidate genes
Most association studies evaluating candidate genes
choose candidates based on their potential role in the
Respiratory Research    Vol 3 No 1 Iannuzzi et al.
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phisms, it is best that they have some plausible biologic
role. However, when a candidate gene is chosen based
on previous linkage with the disease or an intermediate
phenotype, it is more likely that the candidate gene is in
some way involved.
Independent replication in other populations
Polymorphism–disease associations from different popula-
tions are extremely difficult to interpret. Different genetic
variants contributing to the phenotype may be different in
different populations. We therefore cannot expect to gen-
eralize the findings in one ethnic group to another ethnic
group, but we can insist that when an association is found
using a case–control design, it is repeated using a family-
based association study to minimize population stratifica-
tion effects.
Conclusions
We have defined genetic polymorphisms, have pointed
out why their study has become common, and have
reviewed several pitfalls that need to be considered in
designing genetic polymorphism studies and their inter-
pretation. We have discussed association and linkage
studies. Linkage studies can ensure that genes exerting
large effects on disease susceptibility have not been
missed, but will fail to identify genes exerting mild to mod-
erate effects on disease risk. Association studies can
detect genes that exert smaller effects, but cannot be
used to screen the genome. Association studies look at
known genes. TDTs greatly reduce the likelihood that any
allele frequency differences between cases and controls
might be due to unsuspected genetic differences among
subgroups within the population.
A search for disease genes is best accomplished when
both association and linkage strategies are used. We
briefly cited some of the genetic polymorphism studies in
COPD, sarcoidosis, IPF and tuberculosis. Criteria for a
high-quality association study were listed and discussed.
While many have jumped on the genetic polymorphism
bandwagon, those investigators who address the potential
pitfalls will use genetic polymorphisms to provide break-
throughs in understanding disease.
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